Despite limited genomic diversity, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has shown a wide range of clinical manifestations in different patient populations. …

The novel coronavirus SARS-CoV-2 was first detected in the Pacific Northwest region of the
United States in January 2020, with subsequent COVID-19 outbreaks detected in all 50 …

The development of vaccines against SARS-CoV-2 would be greatly facilitated by the
identification of immunological correlates of protection in humans. However, to date, studies on …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has spread globally, with >365,000 cases in California …

We evaluate gene editing of HSV in a well-established mouse model, using adeno-associated
virus (AAV)-delivered meganucleases, as a potentially curative approach to treat latent …

After its emergence in Wuhan, China, in late November or early December 2019, the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus rapidly spread globally. …

More than one year into a global pandemic, SARS-CoV-2 is now defined by a variety of rapidly
evolving variant lineages. Several FDA authorized molecular diagnostic tests have been …

The COVID-19 epidemic of 2019–20 is due to the novel coronavirus SARS-CoV-2. Following
first case description in December, 2019 this virus has infected over 10 million individuals …

Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections
were due to variants of concern (VOCs) and had a median Ct of 20.2 (IQR, 17.1–23.3). When …

Background More than 2 months separated the initial description of SARS-CoV-2 and
discovery of its widespread dissemination in the United States. Despite this lengthy interval, …